Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent β-Thalassemia in England
•Endocrine complications are common in transfusion-dependent β-thalassemia.•Use of healthcare resources is high in transfusion-dependent β-thalassemia compared to matched general population controls.•Patients received a mean of 13.62 red blood cell transfusions per year. Patients with transfusion-de...
Uložené v:
| Vydané v: | Clinical therapeutics Ročník 47; číslo 1; s. 37 - 43 |
|---|---|
| Hlavní autori: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Elsevier Inc
01.01.2025
Elsevier Limited |
| Predmet: | |
| ISSN: | 0149-2918, 1879-114X, 1879-114X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | •Endocrine complications are common in transfusion-dependent β-thalassemia.•Use of healthcare resources is high in transfusion-dependent β-thalassemia compared to matched general population controls.•Patients received a mean of 13.62 red blood cell transfusions per year.
Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England.
This longitudinal, retrospective study linked the Clinical Practice Research Datalink (CPRD) database with secondary care data from the Hospital Episode Statistics database to identify patients with a diagnosis of β-thalassemia between July 1, 2008, and June 30, 2018. Included patients had a diagnosis of β-thalassemia prior to the index date, ≥8 RBCTs per year for ≥2 consecutive years, and ≥1 year of follow-up data available from the index date. Each eligible patient was exact matched with up to 5 controls in the CPRD. Proportions of deaths and rates of mortality, acute and chronic complications, and healthcare resource utilization (HCRU) were calculated during the follow-up period.
Of 11,359 identified patients with β-thalassemia, 237 patients with TDT met the eligibility criteria and were matched with 1184 controls. The mean age at the index date was approximately 25 years in the patient and control groups. The proportion of deaths (7.17% vs 1.18%; P < 0.05) and mortality rate (1.19 deaths per 100 person-years vs 0.20 deaths per 100 person-years) were higher among patients with TDT compared to controls. Endocrine complications and bone disorders were the most prevalent complications among patients with TDT (58.23%) and included osteoporosis (29.11%), diabetes mellitus (28.27%), and hypopituitarism (28.27%). Patients with TDT had a mean of 13.62 RBCTs per patient per year (PPPY). HCRU was substantially higher among patients with TDT, wherein patients with TDT had higher rates of prescriptions recorded in primary care (24.09 vs 8.61 PPPY), outpatient visits (16.69 vs 1.31 PPPY), and inpatient hospitalizations (17.41 vs 0.24 PPPY) than controls. Inpatient hospitalizations were primarily <1 day, with 16.62 events PPPY lasting <1 day and 0.79 events PPPY lasting ≥1 day. Patients with TDT aged ≥18 years had increased rates of mortality, clinical complications, and HCRU than those aged <18 years.
Patients with TDT in England have higher mortality than matched controls, substantial disease-related clinical complications, and substantial HCRU. High mortality and clinical complications highlight the need for additional innovative therapies for TDT. |
|---|---|
| AbstractList | Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England.
This longitudinal, retrospective study linked the Clinical Practice Research Datalink (CPRD) database with secondary care data from the Hospital Episode Statistics database to identify patients with a diagnosis of β-thalassemia between July 1, 2008, and June 30, 2018. Included patients had a diagnosis of β-thalassemia prior to the index date, ≥8 RBCTs per year for ≥2 consecutive years, and ≥1 year of follow-up data available from the index date. Each eligible patient was exact matched with up to 5 controls in the CPRD. Proportions of deaths and rates of mortality, acute and chronic complications, and healthcare resource utilization (HCRU) were calculated during the follow-up period.
Of 11,359 identified patients with β-thalassemia, 237 patients with TDT met the eligibility criteria and were matched with 1184 controls. The mean age at the index date was approximately 25 years in the patient and control groups. The proportion of deaths (7.17% vs 1.18%; P < 0.05) and mortality rate (1.19 deaths per 100 person-years vs 0.20 deaths per 100 person-years) were higher among patients with TDT compared to controls. Endocrine complications and bone disorders were the most prevalent complications among patients with TDT (58.23%) and included osteoporosis (29.11%), diabetes mellitus (28.27%), and hypopituitarism (28.27%). Patients with TDT had a mean of 13.62 RBCTs per patient per year (PPPY). HCRU was substantially higher among patients with TDT, wherein patients with TDT had higher rates of prescriptions recorded in primary care (24.09 vs 8.61 PPPY), outpatient visits (16.69 vs 1.31 PPPY), and inpatient hospitalizations (17.41 vs 0.24 PPPY) than controls. Inpatient hospitalizations were primarily <1 day, with 16.62 events PPPY lasting <1 day and 0.79 events PPPY lasting ≥1 day. Patients with TDT aged ≥18 years had increased rates of mortality, clinical complications, and HCRU than those aged <18 years.
Patients with TDT in England have higher mortality than matched controls, substantial disease-related clinical complications, and substantial HCRU. High mortality and clinical complications highlight the need for additional innovative therapies for TDT. Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England.PURPOSEPatients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England.This longitudinal, retrospective study linked the Clinical Practice Research Datalink (CPRD) database with secondary care data from the Hospital Episode Statistics database to identify patients with a diagnosis of β-thalassemia between July 1, 2008, and June 30, 2018. Included patients had a diagnosis of β-thalassemia prior to the index date, ≥8 RBCTs per year for ≥2 consecutive years, and ≥1 year of follow-up data available from the index date. Each eligible patient was exact matched with up to 5 controls in the CPRD. Proportions of deaths and rates of mortality, acute and chronic complications, and healthcare resource utilization (HCRU) were calculated during the follow-up period.METHODSThis longitudinal, retrospective study linked the Clinical Practice Research Datalink (CPRD) database with secondary care data from the Hospital Episode Statistics database to identify patients with a diagnosis of β-thalassemia between July 1, 2008, and June 30, 2018. Included patients had a diagnosis of β-thalassemia prior to the index date, ≥8 RBCTs per year for ≥2 consecutive years, and ≥1 year of follow-up data available from the index date. Each eligible patient was exact matched with up to 5 controls in the CPRD. Proportions of deaths and rates of mortality, acute and chronic complications, and healthcare resource utilization (HCRU) were calculated during the follow-up period.Of 11,359 identified patients with β-thalassemia, 237 patients with TDT met the eligibility criteria and were matched with 1184 controls. The mean age at the index date was approximately 25 years in the patient and control groups. The proportion of deaths (7.17% vs 1.18%; P < 0.05) and mortality rate (1.19 deaths per 100 person-years vs 0.20 deaths per 100 person-years) were higher among patients with TDT compared to controls. Endocrine complications and bone disorders were the most prevalent complications among patients with TDT (58.23%) and included osteoporosis (29.11%), diabetes mellitus (28.27%), and hypopituitarism (28.27%). Patients with TDT had a mean of 13.62 RBCTs per patient per year (PPPY). HCRU was substantially higher among patients with TDT, wherein patients with TDT had higher rates of prescriptions recorded in primary care (24.09 vs 8.61 PPPY), outpatient visits (16.69 vs 1.31 PPPY), and inpatient hospitalizations (17.41 vs 0.24 PPPY) than controls. Inpatient hospitalizations were primarily <1 day, with 16.62 events PPPY lasting <1 day and 0.79 events PPPY lasting ≥1 day. Patients with TDT aged ≥18 years had increased rates of mortality, clinical complications, and HCRU than those aged <18 years.FINDINGSOf 11,359 identified patients with β-thalassemia, 237 patients with TDT met the eligibility criteria and were matched with 1184 controls. The mean age at the index date was approximately 25 years in the patient and control groups. The proportion of deaths (7.17% vs 1.18%; P < 0.05) and mortality rate (1.19 deaths per 100 person-years vs 0.20 deaths per 100 person-years) were higher among patients with TDT compared to controls. Endocrine complications and bone disorders were the most prevalent complications among patients with TDT (58.23%) and included osteoporosis (29.11%), diabetes mellitus (28.27%), and hypopituitarism (28.27%). Patients with TDT had a mean of 13.62 RBCTs per patient per year (PPPY). HCRU was substantially higher among patients with TDT, wherein patients with TDT had higher rates of prescriptions recorded in primary care (24.09 vs 8.61 PPPY), outpatient visits (16.69 vs 1.31 PPPY), and inpatient hospitalizations (17.41 vs 0.24 PPPY) than controls. Inpatient hospitalizations were primarily <1 day, with 16.62 events PPPY lasting <1 day and 0.79 events PPPY lasting ≥1 day. Patients with TDT aged ≥18 years had increased rates of mortality, clinical complications, and HCRU than those aged <18 years.Patients with TDT in England have higher mortality than matched controls, substantial disease-related clinical complications, and substantial HCRU. High mortality and clinical complications highlight the need for additional innovative therapies for TDT.IMPLICATIONSPatients with TDT in England have higher mortality than matched controls, substantial disease-related clinical complications, and substantial HCRU. High mortality and clinical complications highlight the need for additional innovative therapies for TDT. Highlights•Endocrine complications are common in transfusion-dependent β-thalassemia. •Use of healthcare resources is high in transfusion-dependent β-thalassemia compared to matched general population controls. •Patients received a mean of 13.62 red blood cell transfusions per year. Purpose Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England. Methods This longitudinal, retrospective study linked the Clinical Practice Research Datalink (CPRD) database with secondary care data from the Hospital Episode Statistics database to identify patients with a diagnosis of β-thalassemia between July 1, 2008, and June 30, 2018. Included patients had a diagnosis of β-thalassemia prior to the index date, ≥8 RBCTs per year for ≥2 consecutive years, and ≥1 year of follow-up data available from the index date. Each eligible patient was exact matched with up to 5 controls in the CPRD. Proportions of deaths and rates of mortality, acute and chronic complications, and healthcare resource utilization (HCRU) were calculated during the follow-up period. Findings Of 11,359 identified patients with β-thalassemia, 237 patients with TDT met the eligibility criteria and were matched with 1184 controls. The mean age at the index date was approximately 25 years in the patient and control groups. The proportion of deaths (7.17% vs 1.18%; P < 0.05) and mortality rate (1.19 deaths per 100 person-years vs 0.20 deaths per 100 person-years) were higher among patients with TDT compared to controls. Endocrine complications and bone disorders were the most prevalent complications among patients with TDT (58.23%) and included osteoporosis (29.11%), diabetes mellitus (28.27%), and hypopituitarism (28.27%). Patients with TDT had a mean of 13.62 RBCTs per patient per year (PPPY). HCRU was substantially higher among patients with TDT, wherein patients with TDT had higher rates of prescriptions recorded in primary care (24.09 vs 8.61 PPPY), outpatient visits (16.69 vs 1.31 PPPY), and inpatient hospitalizations (17.41 vs 0.24 PPPY) than controls. Inpatient hospitalizations were primarily <1 day, with 16.62 events PPPY lasting <1 day and 0.79 events PPPY lasting ≥1 day. Patients with TDT aged ≥18 years had increased rates of mortality, clinical complications, and HCRU than those aged <18 years. Implications Patients with TDT in England have higher mortality than matched controls, substantial disease-related clinical complications, and substantial HCRU. High mortality and clinical complications highlight the need for additional innovative therapies for TDT. •Endocrine complications are common in transfusion-dependent β-thalassemia.•Use of healthcare resources is high in transfusion-dependent β-thalassemia compared to matched general population controls.•Patients received a mean of 13.62 red blood cell transfusions per year. Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England. This longitudinal, retrospective study linked the Clinical Practice Research Datalink (CPRD) database with secondary care data from the Hospital Episode Statistics database to identify patients with a diagnosis of β-thalassemia between July 1, 2008, and June 30, 2018. Included patients had a diagnosis of β-thalassemia prior to the index date, ≥8 RBCTs per year for ≥2 consecutive years, and ≥1 year of follow-up data available from the index date. Each eligible patient was exact matched with up to 5 controls in the CPRD. Proportions of deaths and rates of mortality, acute and chronic complications, and healthcare resource utilization (HCRU) were calculated during the follow-up period. Of 11,359 identified patients with β-thalassemia, 237 patients with TDT met the eligibility criteria and were matched with 1184 controls. The mean age at the index date was approximately 25 years in the patient and control groups. The proportion of deaths (7.17% vs 1.18%; P < 0.05) and mortality rate (1.19 deaths per 100 person-years vs 0.20 deaths per 100 person-years) were higher among patients with TDT compared to controls. Endocrine complications and bone disorders were the most prevalent complications among patients with TDT (58.23%) and included osteoporosis (29.11%), diabetes mellitus (28.27%), and hypopituitarism (28.27%). Patients with TDT had a mean of 13.62 RBCTs per patient per year (PPPY). HCRU was substantially higher among patients with TDT, wherein patients with TDT had higher rates of prescriptions recorded in primary care (24.09 vs 8.61 PPPY), outpatient visits (16.69 vs 1.31 PPPY), and inpatient hospitalizations (17.41 vs 0.24 PPPY) than controls. Inpatient hospitalizations were primarily <1 day, with 16.62 events PPPY lasting <1 day and 0.79 events PPPY lasting ≥1 day. Patients with TDT aged ≥18 years had increased rates of mortality, clinical complications, and HCRU than those aged <18 years. Patients with TDT in England have higher mortality than matched controls, substantial disease-related clinical complications, and substantial HCRU. High mortality and clinical complications highlight the need for additional innovative therapies for TDT. |
| Author | Shah, Farrukh Ingleby, Fiona C. Howard, Jo Udeze, Chuka Conner, Sarah C. Li, Nanxin Ly, Nelly F. Fleming, Sophia D. |
| Author_xml | – sequence: 1 givenname: Chuka surname: Udeze fullname: Udeze, Chuka email: chukaudeze1992@gmail.com organization: Vertex Pharmaceuticals Incorporated, Boston, Massachusetts – sequence: 2 givenname: Nelly F. surname: Ly fullname: Ly, Nelly F. organization: IQVIA, London, UK – sequence: 3 givenname: Fiona C. surname: Ingleby fullname: Ingleby, Fiona C. organization: IQVIA, London, UK – sequence: 4 givenname: Sophia D. surname: Fleming fullname: Fleming, Sophia D. organization: IQVIA, London, UK – sequence: 5 givenname: Sarah C. surname: Conner fullname: Conner, Sarah C. organization: Vertex Pharmaceuticals Incorporated, Boston, Massachusetts – sequence: 6 givenname: Jo surname: Howard fullname: Howard, Jo organization: Vertex Pharmaceuticals Incorporated, Boston, Massachusetts – sequence: 7 givenname: Nanxin surname: Li fullname: Li, Nanxin organization: Vertex Pharmaceuticals Incorporated, Boston, Massachusetts – sequence: 8 givenname: Farrukh surname: Shah fullname: Shah, Farrukh organization: Whittington Hospital, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39488494$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks9uEzEQxi1URNPCK4AlLlx2sb3ePz4AClGhSEVIkIreLK93nDhsvMH2IhXxVDwIz4TTpD1EQvQ0svSbbz5_MyfoyA0OEHpGSU4JrV6uct1bF5fgVc4I4zkReSoP0IQ2tcgo5VdHaEIoFxkTtDlGJyGsCCGFKNkjdFwI3jRc8An6NUs6Vqsevx19Bw4r1-FzUH1cauUBf4YwjF4Dvoy2tz9VtIPD0xAGbVWEDn-1cYk_KqcW1i3w3CsXzBgSlHWwAZcUI_7zO5svVa9CgLVV2Dp85hZ9GvQYPTSqD_BkX0_R5buz-ew8u_j0_sNsepHpshQxq0nBOqMb3nJjtBasqwhpSlExUzHNVdkaVRlFiSnbwgCQpqva9KqNEgoILU7Ri53uxg_fRwhRrm3Q0CcPMIxBFpQVZUkZ4wl9foCu0v9dcpeokpU1E4Ik6umeGts1dHLj7Vr5a3mbawJe7QDthxA8GKltvAkvemV7SYnc7lGu5N0e5XaPkghJbmzUB_23I_7fOd11Qgr0hwUvg7bgNHTWg46yG-w9NF4faOj9lXyDawh3iVAZmCTyy_bOtmfGOCGsqa-SwJt_C9zLwl9h8eoh |
| CitedBy_id | crossref_primary_10_3389_fendo_2025_1599437 crossref_primary_10_1182_bloodadvances_2024013695 |
| Cites_doi | 10.1111/trf.16636 10.1182/asheducation-2017.1.265 10.1111/bjh.17091 10.1182/blood-2018-06-818187 10.1002/jha2.282 10.1002/ajh.21049 10.1016/j.blre.2019.100588 10.1111/trf.13513 10.1038/s41598-023-34205-9 10.1016/j.blre.2019.100594 10.1016/S0140-6736(17)31822-6 10.1186/s12913-022-07663-6 10.1016/j.jval.2023.03.588 10.1002/ajh.25429 10.1186/1750-1172-5-11 10.1038/gim.2016.173 10.1093/ije/dyz034 |
| ContentType | Journal Article |
| Copyright | 2024 Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated Copyright © 2024 Vertex Pharmaceuticals Incorporated. Published by Elsevier Inc. All rights reserved. 2024. Vertex Pharmaceuticals Incorporated |
| Copyright_xml | – notice: 2024 Vertex Pharmaceuticals Incorporated – notice: Vertex Pharmaceuticals Incorporated – notice: Copyright © 2024 Vertex Pharmaceuticals Incorporated. Published by Elsevier Inc. All rights reserved. – notice: 2024. Vertex Pharmaceuticals Incorporated |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7X8 |
| DOI | 10.1016/j.clinthera.2024.09.024 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Economics Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 43 |
| ExternalDocumentID | 39488494 10_1016_j_clinthera_2024_09_024 S014929182400287X 1_s2_0_S014929182400287X |
| Genre | Journal Article |
| GeographicLocations | England United Kingdom--UK |
| GeographicLocations_xml | – name: England – name: United Kingdom--UK |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- ~HD 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG 6I. AAFTH 9DU AAYXX AFFHD CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c559t-7032dfc84b4ffcc92d60085962f62c4a5bfa6fa10f5b3fee08d6b10f7fa9ae013 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001413765000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0149-2918 1879-114X |
| IngestDate | Sun Sep 28 04:16:02 EDT 2025 Sat Nov 29 15:00:46 EST 2025 Mon Jul 21 05:59:33 EDT 2025 Sat Nov 29 06:32:56 EST 2025 Tue Nov 18 21:09:05 EST 2025 Sat Jan 18 16:10:00 EST 2025 Mon Feb 24 20:12:03 EST 2025 Tue Oct 14 19:31:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Economics CPRD IMD TDT Mortality Transfusion-dependent β-thalassemia RBCT PPPY Clinical complications SD HES Healthcare resource utilization HCRU per patient per year red blood cell transfusion Index of Multiple Deprivation Hospital Episode Statistics Clinical Practice Research Datalink standard deviation |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2024 Vertex Pharmaceuticals Incorporated. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-7032dfc84b4ffcc92d60085962f62c4a5bfa6fa10f5b3fee08d6b10f7fa9ae013 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.clinicalkey.es/playcontent/1-s2.0-S014929182400287X |
| PMID | 39488494 |
| PQID | 3152572990 |
| PQPubID | 1226358 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_3123551224 proquest_journals_3152572990 pubmed_primary_39488494 crossref_citationtrail_10_1016_j_clinthera_2024_09_024 crossref_primary_10_1016_j_clinthera_2024_09_024 elsevier_sciencedirect_doi_10_1016_j_clinthera_2024_09_024 elsevier_clinicalkeyesjournals_1_s2_0_S014929182400287X elsevier_clinicalkey_doi_10_1016_j_clinthera_2024_09_024 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-01-01 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Bridgewater |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Hossain, Islam, Munni (bib0025) 2023; 13 Wolf, Dedman, Campbell (bib0014) 2019; 48 Weiss, Parisi Jun, Sheth (bib0010) 2019; 94 Taher, Cappellini (bib0019) 2018; 132 Cappellini, Cohen, Porter (bib0008) 2014 Delea, Hagiwara, Thomas (bib0009) 2008; 83 National Health Service. Taher, Saliba (bib0021) 2017; 2017 Office for National Statistics. How has life expectancy changed over time? 2020/21. Scottish Paediatric and Adult Haemoglobinopathies Network. Annual Tang, Furnback, Wang (bib0023) 2021; 61 Jobanputra, Paramore, Laird (bib0005) 2020; 191 Medicine and Healthcare Products Regulatory Agency. Release notes: CPRD aurum March 2022. 2021/22. Available from Udeze, Ly, Ingleby (bib0011) 2023; 26 Weidlich, Kefalas, Guest (bib0012) 2016; 56 Office for National Statistics. Average age at death, by sex, UK Galanello, Origa (bib0001) 2010; 5 betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia. Shah, Telfer, Velangi (bib0024) 2021; 2 Taher, Weatherall, Cappellini (bib0003) 2018; 391 Alshamsi, Hamidi, Narci (bib0022) 2022; 22 Origa (bib0002) 2017; 19 Shah, Sayani, Trompeter (bib0007) 2019; 37 . Pinto, Poggi, Russo (bib0020) 2019; 38 Single National Hemoglobinopathy Registry. Annual Weiss (10.1016/j.clinthera.2024.09.024_bib0010) 2019; 94 Galanello (10.1016/j.clinthera.2024.09.024_bib0001) 2010; 5 10.1016/j.clinthera.2024.09.024_bib0015 10.1016/j.clinthera.2024.09.024_bib0013 Cappellini (10.1016/j.clinthera.2024.09.024_bib0008) 2014 Shah (10.1016/j.clinthera.2024.09.024_bib0007) 2019; 37 Delea (10.1016/j.clinthera.2024.09.024_bib0009) 2008; 83 Jobanputra (10.1016/j.clinthera.2024.09.024_bib0005) 2020; 191 10.1016/j.clinthera.2024.09.024_bib0006 Wolf (10.1016/j.clinthera.2024.09.024_bib0014) 2019; 48 Udeze (10.1016/j.clinthera.2024.09.024_bib0011) 2023; 26 Weidlich (10.1016/j.clinthera.2024.09.024_bib0012) 2016; 56 Alshamsi (10.1016/j.clinthera.2024.09.024_bib0022) 2022; 22 Tang (10.1016/j.clinthera.2024.09.024_bib0023) 2021; 61 10.1016/j.clinthera.2024.09.024_bib0004 Taher (10.1016/j.clinthera.2024.09.024_bib0003) 2018; 391 Shah (10.1016/j.clinthera.2024.09.024_bib0024) 2021; 2 Hossain (10.1016/j.clinthera.2024.09.024_bib0025) 2023; 13 Origa (10.1016/j.clinthera.2024.09.024_bib0002) 2017; 19 Pinto (10.1016/j.clinthera.2024.09.024_bib0020) 2019; 38 10.1016/j.clinthera.2024.09.024_bib0018 10.1016/j.clinthera.2024.09.024_bib0017 10.1016/j.clinthera.2024.09.024_bib0016 Taher (10.1016/j.clinthera.2024.09.024_bib0021) 2017; 2017 Taher (10.1016/j.clinthera.2024.09.024_bib0019) 2018; 132 |
| References_xml | – volume: 22 start-page: 304 year: 2022 ident: bib0022 article-title: Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study publication-title: BMC Health Serv Res – volume: 19 start-page: 609 year: 2017 end-page: 619 ident: bib0002 article-title: Beta-thalassemia publication-title: Genet Med – volume: 37 start-page: 100588 year: 2019 ident: bib0007 article-title: Challenges of blood transfusions in beta-thalassemia publication-title: Blood Rev – volume: 391 start-page: 155 year: 2018 end-page: 167 ident: bib0003 article-title: Thalassaemia publication-title: Lancet – reference: National Hemoglobinopathy Registry. Annual – reference: . Available from: – reference: : betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia. – reference: Single – volume: 132 start-page: 1781 year: 2018 end-page: 1791 ident: bib0019 article-title: How I manage medical complications of beta-thalassemia in adults publication-title: Blood – reference: National Health Service. – volume: 26 start-page: S111 year: 2023 ident: bib0011 article-title: EE287 Healthcare resource utilization among patients with transfusion-dependent beta-thalassemia in England publication-title: Value Health – reference: Scottish Paediatric and Adult Haemoglobinopathies Network. Annual – volume: 83 start-page: 263 year: 2008 end-page: 270 ident: bib0009 article-title: Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States publication-title: Am J Hematol – volume: 13 start-page: 7734 year: 2023 ident: bib0025 article-title: Health-related quality of life among thalassemia patients in Bangladesh using the SF-36 questionnaire publication-title: Sci Rep – volume: 5 start-page: 11 year: 2010 ident: bib0001 article-title: Beta-thalassemia publication-title: Orphanet J Rare Dis – volume: 94 start-page: E129 year: 2019 end-page: E132 ident: bib0010 article-title: Clinical and economic burden of regularly transfused adult patients with beta-thalassemia in the United States: a retrospective cohort study using payer claims publication-title: Am J Hematol – reference: Office for National Statistics. How has life expectancy changed over time? – volume: 2 start-page: 738 year: 2021 end-page: 749 ident: bib0024 article-title: Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent beta-thalassaemia in the United Kingdom: a mixed methods observational study publication-title: EJHaem – reference: . – reference: 2021/22. – reference: Office for National Statistics. Average age at death, by sex, UK – volume: 191 start-page: 897 year: 2020 end-page: 905 ident: bib0005 article-title: Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis publication-title: Br J Haematol – volume: 38 start-page: 100594 year: 2019 ident: bib0020 article-title: Management of the aging beta-thalassemia transfusion-dependent population – the Italian experience publication-title: Blood Rev – volume: 2017 start-page: 265 year: 2017 end-page: 271 ident: bib0021 article-title: Iron overload in thalassemia: different organs at different rates publication-title: Hematology Am Soc Hematol Educ Program – reference: 2020/21. – volume: 56 start-page: 1038 year: 2016 end-page: 1045 ident: bib0012 article-title: Healthcare costs and outcomes of managing beta-thalassemia major over 50 years in the United Kingdom publication-title: Transfusion – year: 2014 ident: bib0008 publication-title: Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) – reference: Medicine and Healthcare Products Regulatory Agency. Release notes: CPRD aurum March 2022. – volume: 61 start-page: 2906 year: 2021 end-page: 2917 ident: bib0023 article-title: Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: a real-world analysis publication-title: Transfusion – volume: 48 year: 2019 ident: bib0014 article-title: Data resource profile: Clinical Practice Research Datalink (CPRD) aurum publication-title: Int J Epidemiol – ident: 10.1016/j.clinthera.2024.09.024_bib0015 – volume: 61 start-page: 2906 year: 2021 ident: 10.1016/j.clinthera.2024.09.024_bib0023 article-title: Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: a real-world analysis publication-title: Transfusion doi: 10.1111/trf.16636 – ident: 10.1016/j.clinthera.2024.09.024_bib0017 – volume: 2017 start-page: 265 year: 2017 ident: 10.1016/j.clinthera.2024.09.024_bib0021 article-title: Iron overload in thalassemia: different organs at different rates publication-title: Hematology Am Soc Hematol Educ Program doi: 10.1182/asheducation-2017.1.265 – volume: 191 start-page: 897 year: 2020 ident: 10.1016/j.clinthera.2024.09.024_bib0005 article-title: Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis publication-title: Br J Haematol doi: 10.1111/bjh.17091 – ident: 10.1016/j.clinthera.2024.09.024_bib0013 – volume: 132 start-page: 1781 year: 2018 ident: 10.1016/j.clinthera.2024.09.024_bib0019 article-title: How I manage medical complications of beta-thalassemia in adults publication-title: Blood doi: 10.1182/blood-2018-06-818187 – volume: 2 start-page: 738 year: 2021 ident: 10.1016/j.clinthera.2024.09.024_bib0024 article-title: Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent beta-thalassaemia in the United Kingdom: a mixed methods observational study publication-title: EJHaem doi: 10.1002/jha2.282 – volume: 83 start-page: 263 year: 2008 ident: 10.1016/j.clinthera.2024.09.024_bib0009 article-title: Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States publication-title: Am J Hematol doi: 10.1002/ajh.21049 – volume: 37 start-page: 100588 year: 2019 ident: 10.1016/j.clinthera.2024.09.024_bib0007 article-title: Challenges of blood transfusions in beta-thalassemia publication-title: Blood Rev doi: 10.1016/j.blre.2019.100588 – volume: 56 start-page: 1038 year: 2016 ident: 10.1016/j.clinthera.2024.09.024_bib0012 article-title: Healthcare costs and outcomes of managing beta-thalassemia major over 50 years in the United Kingdom publication-title: Transfusion doi: 10.1111/trf.13513 – volume: 13 start-page: 7734 year: 2023 ident: 10.1016/j.clinthera.2024.09.024_bib0025 article-title: Health-related quality of life among thalassemia patients in Bangladesh using the SF-36 questionnaire publication-title: Sci Rep doi: 10.1038/s41598-023-34205-9 – volume: 38 start-page: 100594 year: 2019 ident: 10.1016/j.clinthera.2024.09.024_bib0020 article-title: Management of the aging beta-thalassemia transfusion-dependent population – the Italian experience publication-title: Blood Rev doi: 10.1016/j.blre.2019.100594 – volume: 391 start-page: 155 year: 2018 ident: 10.1016/j.clinthera.2024.09.024_bib0003 article-title: Thalassaemia publication-title: Lancet doi: 10.1016/S0140-6736(17)31822-6 – ident: 10.1016/j.clinthera.2024.09.024_bib0016 – ident: 10.1016/j.clinthera.2024.09.024_bib0018 – volume: 22 start-page: 304 year: 2022 ident: 10.1016/j.clinthera.2024.09.024_bib0022 article-title: Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study publication-title: BMC Health Serv Res doi: 10.1186/s12913-022-07663-6 – volume: 26 start-page: S111 year: 2023 ident: 10.1016/j.clinthera.2024.09.024_bib0011 article-title: EE287 Healthcare resource utilization among patients with transfusion-dependent beta-thalassemia in England publication-title: Value Health doi: 10.1016/j.jval.2023.03.588 – year: 2014 ident: 10.1016/j.clinthera.2024.09.024_bib0008 – ident: 10.1016/j.clinthera.2024.09.024_bib0004 – volume: 94 start-page: E129 year: 2019 ident: 10.1016/j.clinthera.2024.09.024_bib0010 article-title: Clinical and economic burden of regularly transfused adult patients with beta-thalassemia in the United States: a retrospective cohort study using payer claims publication-title: Am J Hematol doi: 10.1002/ajh.25429 – volume: 5 start-page: 11 year: 2010 ident: 10.1016/j.clinthera.2024.09.024_bib0001 article-title: Beta-thalassemia publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-5-11 – volume: 19 start-page: 609 year: 2017 ident: 10.1016/j.clinthera.2024.09.024_bib0002 article-title: Beta-thalassemia publication-title: Genet Med doi: 10.1038/gim.2016.173 – ident: 10.1016/j.clinthera.2024.09.024_bib0006 – volume: 48 year: 2019 ident: 10.1016/j.clinthera.2024.09.024_bib0014 article-title: Data resource profile: Clinical Practice Research Datalink (CPRD) aurum publication-title: Int J Epidemiol doi: 10.1093/ije/dyz034 |
| SSID | ssj0003952 |
| Score | 2.4624507 |
| Snippet | •Endocrine complications are common in transfusion-dependent β-thalassemia.•Use of healthcare resources is high in transfusion-dependent β-thalassemia compared... Highlights•Endocrine complications are common in transfusion-dependent β-thalassemia. •Use of healthcare resources is high in transfusion-dependent... Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with... Purpose Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload.... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 37 |
| SubjectTerms | Adolescent Adult Age beta-Thalassemia - complications beta-Thalassemia - economics beta-Thalassemia - mortality beta-Thalassemia - therapy Blood diseases Blood Transfusion Bone diseases Cell survival Chelation Chelation therapy Child Child, Preschool Clinical complications Cost of Illness Databases, Factual Demographics Diabetes mellitus Diagnosis Disease management DNA nucleotidylexotransferase Economics England - epidemiology Erythrocyte Transfusion - economics Erythrocytes Erythropoiesis Ethnicity Fatalities Female Health care Health services utilization Healthcare resource utilization Hemoglobin Humans Hypopituitarism Internal Medicine Iron Iron Chelating Agents - therapeutic use Longitudinal Studies Male Medical diagnosis Medical records Middle Aged Mortality Osteoporosis Patient Acceptance of Health Care - statistics & numerical data Patients Population Primary care Resource utilization Retrospective Studies Socioeconomic factors Socioeconomic status Survival analysis Thalassemia Transfusion-dependent β-thalassemia Young Adult |
| Title | Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent β-Thalassemia in England |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S014929182400287X https://www.clinicalkey.es/playcontent/1-s2.0-S014929182400287X https://dx.doi.org/10.1016/j.clinthera.2024.09.024 https://www.ncbi.nlm.nih.gov/pubmed/39488494 https://www.proquest.com/docview/3152572990 https://www.proquest.com/docview/3123551224 |
| Volume | 47 |
| WOSCitedRecordID | wos001413765000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1879-114X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AIEXJ dateStart: 20130901 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1879-114X dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1879-114X dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1879-114X dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1879-114X dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1879-114X dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZgQ4gXLuNWGJOR0J5mkThuHPOCAG3aAyvV1EHfrMQXLaikY0mR9sCf4ofwm_Bx7FRIjCHx4ipqT1PVJ-d8x-fyIfQi1XnucLwmRUUVYSzLSCFoRYziZVFlnLHSD3F9zyeTYj4X03Dg1oayymgTvaHWSwVn5C8zIOrhYDxfn30lwBoF2dVAoXEdbabgu50-8-OPgyXOhGfcgSiAUJEWv9V3Qeeh73FyQSLth51Sdpl3ugx9ei90cOd_f_9ddDvgT_ymV5h76JppttDNo5Bh30K7036W9cUenq1bs9o9vIun6ynXF_fR9zBRdIH7TghcNhofDtVkOOYF8ElXL0KzJ47KYDT-VHenOLIkYe8y7QqO7kjk5e3wzx-YzE6h07M1X-oS1w0OpCMP0MnB_uzdIQlcDkS5mKUjzrBQbVXBKmatUoLqHNCeyKnNqWLluLJlbss0seMqs8Ykhc4rd8UtjA93OPUh2miWjXmMMHUeVSmdaRcaMq7HFVOs0qnmqsyUgyQjlMc9lCoMOge-jYWMFW2f5bD5EjZfJkK6lxFKBsGzftbH1SJFVBIZW1md8ZXOH10tyv8katpgRFqZypbKxNffCVBfKPd1Ae58hF4NkgEn9fjn3267HfVTDndaK-cIPR_edoYGskdlY5Yr-Ax12BQSsSP0qH8Ghn8pE84PMMGe_P3Ln6JbFOiT_QnWNtrozlfmGbqhvnV1e77jn11Y59yvxQ7afLs_mR67q6NkBiv98AuBzFV5 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgigXHuUVKLBI0FNX2OuN10ZCCAFVqqZRDqnIbbF316qr4JTaAeXAX-LAD-E3sWN7HSFRyqUHTlbkjC2t5_HN7sx8AM98HYYWx2sapUxRzoOARjFLqVEiidJAcJ7UQ1yHYjSKptN4vAbfXS8MllU6n1g7aj1XuEf-IkCiHoHO8_XJZ4qsUXi66ig0GrXYN8uvNmUrX-29s9_3OWO77ydvB7RlFaDKoueKWhVnOlMRT3mWKRUzHSLuiEOWhUzxpJ9mSZglvpf10yAzxot0mNpfIsNB1hYx2edegsvWjwssIRPTLsHzgrhm-MGsg7LYj36rJ8NOx7qnyialrBmuyvhZ0fAstFtHvd0b_9t63YTrLb4mbxqDuAVrptiEqwdtBcEmbI-bWd3LHTJZtZ6VO2SbjFdTvJe34Vs7MXVGmk4PkhSaDLpqOeLOPchhlc_aZlbilN1o8iGvjohjgSI1JMgWuDVJHe9wRX7-IHRyhJ2spfmUJyQvSEuqcgcOL2SV7sJ6MS_MfSDMIgaldKBt6suF7qdc8VT7WqgkUBZy9SB0OiNVO8gd-URm0lXsHctO2SQqm_RiaS898DrBk2aWyfkikVNK6Vp1bXCRNt6eLyr-JGrK1kmW0pclk15dXxijuWA5s03gpz142Um2OLDBd__22i1nD7J708oYevC0u20dKZ6OJYWZL_A_zGJvPGjuwb3G5rpVCmIb53jMH_z94U9gYzA5GMrh3mj_IVxjSBVd79ZtwXp1ujCP4Ir6UuXl6ePabxD4eNGG9wuBV69t |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgiouPMorUGCRoKeuaq83fiAhhChRq7ZRDqnIbbH3obpKnVI7oBz4Uxz5EfwmdmyvIyRKufTAyYqcsaX1PL7ZnZkP4KWvwtDieEXjjEnKeRDQOGEZ1TJK4yyIOE_rIa4H0XAYTybJaAV-uF4YLKt0PrF21GomcY98O0Cingid57ZpyyJGO4O3Z58pMkjhSauj02hUZF8vvtr0rXyzt2O_9SvGBh_G73dpyzBApUXSFbXqzpSRMc-4MVImTIWIQZKQmZBJnvYzk4Ym9T3TzwKjtRerMLO_IoNDrS16ss-9Btcj3mdYTnbojbsoECQ12w9mIJQlfvxbbRl2Pdb9VTZBZc2gVcYviowXId86Ag5u_89rdwdutbibvGsM5S6s6GId1g7byoJ12Bw1M7wXW2S8bEkrt8gmGS2ney_uwbd2kuqUNB0gJC0U2e2q6Ig7DyFHVT5tm1yJMwKtyMe8OiaOHYrUUMHMccuSOj7iivz8Tuj4GDtcS32apyQvSEu2ch-OrmSVHsBqMSv0IyDMIgkpVaBsSswj1c-45JnyVSTTQFoo1oPQ6Y-Q7YB35BmZClfJdyI6xROoeMJLhL30wOsEz5oZJ5eLxE5BhWvhtUFH2Dh8uWj0J1Fdts6zFL4omfDqusMETQfLnG1iP-nB606yxYcN7vu312442xDdm5aG0YMX3W3rYPHULC30bI7_YRaT4wF0Dx429tetUpDY-McT_vjvD38Oa9bexMHecP8J3GTIIF1v4m3AanU-10_hhvxS5eX5s9qFEPh01Xb3C4rXuD0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Burden+and+Healthcare+Resource+Utilization+Associated+With+Managing+Transfusion-dependent+%CE%B2-Thalassemia+in+England&rft.jtitle=Clinical+therapeutics&rft.au=Udeze%2C+Chuka&rft.au=Ly%2C+Nelly+F&rft.au=Ingleby%2C+Fiona+C&rft.au=Fleming%2C+Sophia+D&rft.date=2025-01-01&rft.issn=1879-114X&rft.eissn=1879-114X&rft_id=info:doi/10.1016%2Fj.clinthera.2024.09.024&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291824X00132%2Fcov150h.gif |